Skip to main content
Premium Trial:

Request an Annual Quote

Ionpath Closes $18M Series B Round

NEW YORK – Spatial proteomics firm Ionpath said on Thursday that it has closed an $18 million Series B financing round.

Led by Samsara BioCapital, the round also included new investor Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging (MIBI) technology, Rohan Thakur, executive VP at Bruker, said in a statement.

Existing investors including Genoa Ventures, ND Capital, Paladin Partners Investments, Trancos Ionpath Investors, Norwich Ventures, and Vertical Venture Partners Growth Fund also contributed to the round.

"Developed by pathologists for translational researchers, Ionpath’s MIBI platform delivers a revolutionary way to visualize phenotypic profiles, enabling rich, sensitive spatial analysis of tissue microenvironments," Mike Dybbs, partner at Samsara BioCapital and Ionpath board member, said in a statement. "We are excited to support Ionpath in its mission to advance precision medicine and we are proud to partner with Bruker and all the company’s investors on this financing."

"We are seeing strong traction for our MIBI technology, both in our MIBIscope instrument and our end-to-end Research Services business. We are more convinced than ever that MIBI-enabled, high-definition spatial proteomics will be a key enabler for the deployment of precision medicine in the treatment of a wide range of diseases," said Ionpath CEO Sander Gubbens.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.